focus -WSS

focus

author：focus 2025-09-29 20:00:13 - browse：95859

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： The FDA weighs the risks of candy

hotspot

focus

WSS

Why Sanofi got shellacked over its spinoff

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Following judge's order, DOJ releases slightly less

CDC recommends rationing of RSV shot due to shortages

Telehealth options flood the market as retailers push virtual care

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pope Francis asks Church to identify 21st

State Dept. review finds Biden bears some blame for Afghanistan failures

Israel withdraws forces after 2

23andMe had bad news about my health. I wish a person had delivered it

Testing for cancer recurrence creates a new limbo for patients

Psychedelics group wrestles with new pharma identity

Maker of FluMist seeks to allow at

Cancer drug shortages should be causing more outrage

Telehealth options flood the market as retailers push virtual care

leisure time

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

CDC recommends rationing of RSV shot due to shortages

Telehealth options flood the market as retailers push virtual care

Search warrant issued in 1996 disappearance of Kristin Smart

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

hotspot

hotspot

focus

hotspot